NEW YORK, November 17, 2017 /PRNewswire/ --
According to a report by Grand View Research (GVR), the global biotechnology market is expected to reach USD 727.1 billion by 2025. Major technological advancements in segments such as regenerative medicine and
genetics in diagnostics are important drives for the future of biotechnology. Innovative companies in the industry are engaged in
large clinical trials and strong R&D investments for cancer therapeutics, as oncology is one of the most promising areas of
focus in the biotech industry. Regen Biopharma, Inc. (OTC: RGBP), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), Inovio
Pharmaceuticals Inc. (NASDAQ: INO), OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), ImmunoGen, Inc. (NASDAQ: IMGN).
"Rising incidence of oncology diseases is anticipated to drive the demand for next-generation cancer diagnostic tests. These
tests are expected to facilitate early diagnosis and enable efficient prognosis of various forms of cancer, which in turn, is
expected to positively influence progress of this vertical over the forecast period. Development and introduction of product
offerings by a number of large entities is a significant factor expected to provide lucrative growth avenues to this market,
active participation of global organizations, such as National Cancer Institute, Cancer Research Institute, National Foundation
for Cancer Research, and Cancer Research UK, are supportive of the projected sector progress," GVR reports.
Regen Bio P harma, Inc. (OTCQB: RGBP) announced breaking news after the
market close that it has, "commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6
nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem
cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the
cancer-killing potential of a patient's own immune system. Regen is also engaged in the identification of small molecules
which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders."
"The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward - if inhibiting the
checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should
suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid
arthritis, lupus, colitis and many other autoimmune diseases," says David Koos, Ph.D., Chairman and CEO of Regen. "Our
program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are
focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.). The benefits of
small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control
of toxicity and intellectual property protection."
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) is a clinical-stage patient-focused biopharmaceutical company developing
novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Recently, the company announced
updated translational data from the ongoing Phase 1/2 study of intratumoral IMO-2125 in combination with ipilimumab for the
treatment of anti-PD-1 refractory metastatic melanoma. IMO-2125 is a toll-like receptor (TLR) 9 agonist that received orphan drug
designation from the FDA in 2017 for the treatment of melanoma Stages IIb to IV. It signals the immune system to create and
activate cancer-fighting cells (T-cells) to target solid tumors in refractory melanoma patients.
Inovio Pharmaceuticals Inc. (NASDAQ: INO) is taking immunotherapy to the next level in the fight against cancer and
infectious diseases. Recently, the company announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell
stimulation in phase 1 studies. INO-3112 (now called MEDI0457), an investigational T-cell activation immunotherapy that targets
cancers caused by human papillomavirus (HPV) types 16 and 18 and licensed to MedImmune, the global Research and Development arm
of AstraZeneca, also led to a head and neck cancer patient's complete response when matched with a PD-1 checkpoint inhibitor. In
addition, INO-1400, Inovio's investigational cancer immunotherapy targeting hTERT, which is over-expressed in a majority of
cancers, generated hTERT-specific IFN-γ secreting T cells, suggesting an ability to break immune tolerance.
OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) is a clinical-stage biopharmaceutical company focused on discovering and
developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended
to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. On November 02, 2017, the company announced third quarter financial results. As of September 30, 2017, cash, cash equivalents and short-term investments totaled $113.6
million. In September, OncoMed dosed the first patient in a Phase 1a single agent study of its wholly-owned GITRL-Fc in
patients with advanced or metastatic solid tumors. GITRL-Fc is a fusion protein with an Fc-linked fully human trimer ligand and
is designed to activate the co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptor) to enhance
T-cell modulated immune responses. The Phase 1a study is designed to assess safety and tolerability of escalating doses.
ImmunoGen, Inc. (NASDAQ: IMGN) is a clinical-stage biotechnology company that develops targeted cancer therapeutics using
its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for
FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease.
On November 3, 2017, the company reviewed recent highlights and reported financial results for the
quarter ended September 30, 2017. Investigational new drug (IND) application activated to support
clinical testing with IMGN632, a CD123-targeting ADC integrating a potent DNA-alkylating payload intended to treat a range of
hematological malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Revenues for the quarter ended September 30, 2017 were $8.5 million,
compared to $7.7 million for the quarter ended September 30,
2016.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in
this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information
posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality
and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not
offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with
financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique
financial newswire and media platform. For this release, FinancialBuzz.com expects to be compensated five
thousand dollars for financial news dissemination and pr services by a non-affiliate third party for Regen BioPharma, Inc.
Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or
a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the
balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in
securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the
information on the editorial or Site or continue to post information about any companies the information contained herein is not
intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation.
The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members
and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site,
company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors
accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation
of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and
website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time.
None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any
particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication
is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment
strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree
to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no
representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change
without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.
For further information:
info@financialbuzz.com
+1-877-601-1879
URL: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com